What question did this study set out to answer?

To determine how cellular dynamics, expansion, and baseline immune profiles of BCMA-targeted CAR T cells relate to clinical response, resistance, and toxicity in relapsed/refractory multiple myeloma.

January 6, 2024LeukemiaOpen Access

Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma

View Full Paper

Ask AI

Bookmark

Authors

LFLuise Fischer NGNora Grieb PBPatrick Born

Discussion

Member takes

Overview

Cohort study reveals CD8+ CAR T cell expansion predicts clinical response and toxicity risk in refractory myeloma, highlighting opportunities for early patient stratification.

Key Points

To determine how cellular dynamics, expansion, and baseline immune profiles of BCMA-targeted CAR T cells relate to clinical response, resistance, and toxicity in relapsed/refractory multiple myeloma.
Conducted comprehensive flow cytometric profiling in N=27 patients with relapsed/refractory multiple myeloma receiving idecabtagene vicleucel (Ide-cel).
Assessed in vivo CAR T cell expansion, persistence, bystander immune cell interactions, and cellular markers from leukapheresis through post-infusion follow-up.
In vivo expansion of CD8+ CAR T cells correlated positively with therapeutic response, whereas long-term cellular persistence was not necessary for durable remission.
An enriched CD8+ T cell subset at leukapheresis alongside effective lymphodepletion correlated with improved clinical outcomes.
Patient risk profiles for developing higher-grade cytokine release syndrome were detectable prior to the start of lymphodepletion.

Cite This Study

Fischer et al. (2024) studied this question.

synapsesocial.com/papers/6aae4bdcd10271d2131c2749 https://doi.org/10.1038/s41375-023-02129-y

View Full Paper

Ask AI

Bookmark

January 6, 2024LeukemiaOpen Access

Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma

View Full Paper

Ask AI

Bookmark

Authors

LFLuise Fischer NGNora Grieb PBPatrick Born

Discussion

Member takes

Overview

Cohort study reveals CD8+ CAR T cell expansion predicts clinical response and toxicity risk in refractory myeloma, highlighting opportunities for early patient stratification.

Key Points

To determine how cellular dynamics, expansion, and baseline immune profiles of BCMA-targeted CAR T cells relate to clinical response, resistance, and toxicity in relapsed/refractory multiple myeloma.
Conducted comprehensive flow cytometric profiling in N=27 patients with relapsed/refractory multiple myeloma receiving idecabtagene vicleucel (Ide-cel).
Assessed in vivo CAR T cell expansion, persistence, bystander immune cell interactions, and cellular markers from leukapheresis through post-infusion follow-up.
In vivo expansion of CD8+ CAR T cells correlated positively with therapeutic response, whereas long-term cellular persistence was not necessary for durable remission.
An enriched CD8+ T cell subset at leukapheresis alongside effective lymphodepletion correlated with improved clinical outcomes.
Patient risk profiles for developing higher-grade cytokine release syndrome were detectable prior to the start of lymphodepletion.

Cite This Study

Fischer et al. (2024) studied this question.

synapsesocial.com/papers/6aae4bdcd10271d2131c2749 https://doi.org/10.1038/s41375-023-02129-y

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark